Gallbladder carcinoma associated with pancreatobiliary reflux

Table 1 Clinical characteristics of patients with on-pancreaticobiliary maljunction

	Age	Sex	Biliary amylase(IU/L)	Common channel length (mm)	Pathology	Depth of invasion	GB stone	Choledocal cyst
1	56	M	47 190	7	Hyperplasia		+	-
2	69	F	27 038	8	Hyperplasia		+	-
3	63	F	61 710	4	Hyperplasia		-	-
4	53	F	52 600	8	ca	m	-	-
5	68	F	84 700	9	ca	m	-	-
6	70	F	64 260	4	ca	ss	-	-
7	65	F	12 030	18	chr-itis		+	+
8	74	F	153 000	16	chr-itis		+	-
9	63	M	136 400	48	ADM		-	+
10	34	F	145 000	15	Hyperplasia		+	-
11	46	F	103 500	26	Hyperplasia		-	-
12	40	F	126 900	28	Hyperplasia		+	+
13	47	M	95 400	19	ca	m	-	-
14	54	F	132 180	27	ca	ss	-	-
15	64	F	177 520	24	ca	ss	-	-
16	75	F	26 510	20	ca	ss	-	-
17	57	F	21 100	19	ca	ss	-	-

GB: Gallbladder; m: Tumor invades the mucosa; ss: Tumor invades the subserosa; ca: Adenocarcinoma. se: Tumor perforates serosa; chr-it is: Chronic cholecystitis; ADM: Adenomyomatosis;

Table 2 Clinicopathological findings in patients with and without pancreaticobiliary maljunction

	non-PBM(n = 6)	PBM (n = 11)
Age (mean ± SD)	63.2 ± 7.2	54.1 ± 12
Female (number)	5/6 (83%)	9/11 (82%)
CBD-Amy (mean ± SD) IU/L	56 250 ± 19 246	102 686 ± 57 660
Cholecystolithiasis (number)	2/6 (33%)	4/11 (36%)
Length of the common channel (mean ± SD) mm	6.7 ± 2.2	23.6 ± 9.2
Gallbladder carcinoma (number)	3/6 (50%)	5/11 (46%)

PBM: Pancreaticobiliary maljunction; CBD-Amy: Amylase levels in the common bile duct; SD: Standard deviation.